Skip to content
SigiPulse
All trends
healthcare·DecliningLive

STAT+: Lilly’s triple-G drug beats Ozempic in head-to

0%Detected 3d ago·4 sources·🌍·Peaks in ~0h
Personalize this

Get Personalized Trend Intelligence

Pulse will surface trends in your niche, ranked by opportunity — not generic feeds.

Start free
Viral Score
33/100
45% confidence
Controversy
0/100
Low risk
Opportunity
55/100
Content potential
📡Mentions this hour
3
📰Publishers
2
🔥Engagement
25/100
⏱Window left
~0h

Why It's Trending

AI

[Healthcare] Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study. [Healthcare] Data add to expectations that the drug will be one of Lilly’s greatest growth drivers.

Powered by SigiPulse · Sourced from statnews.com, medcitynews.com +2 more

Audience Sentiment

65% Positive12% Neutral23% Negative

Predominantly positive. Safe to post.

Trend Lifecycle

Emerging
Growing
Viral
Peak
5
Declining
6
Dead
Expected peak in ~0h83%

Score History

Last 12 hours
Viral scoreControversy

Platform Breakdown

News outlets100%

Geographic Reach

🌍 Global — no single country dominates this trend.

Content Ideas

48+ ideas
reels hook

POV: You're watching STAT+: Lilly’s triple-G drug beats Ozempic in head-to unfold live

Low engagement
reels hook

STAT+: Lilly’s triple-G drug beats Ozempic in head-to — explained in 60 seconds

Medium engagement
reels hook

Where were you when STAT+: Lilly’s triple-G drug beats Ozempic in head-to happened?

High engagement
reels hook

The moment everyone missed about STAT+: Lilly’s triple-G drug beats Ozempic in head-to

Low engagement
reels hook

STAT+: Lilly’s triple-G drug beats Ozempic in head-to: the timeline nobody is talking about

Medium engagement
reels hook

What STAT+: Lilly’s triple-G drug beats Ozempic in head-to actually means for the next 24 hours

High engagement

Linked Sources

More like this

Unlock More Opportunities Like This

Members see the full set of related trends, AI briefs, and a personalized daily digest.

Unlock for free

Trending now

View all
Free forever — no card

Create your free account

Stop browsing trends. Start acting on them — with AI briefs tuned to your niche.

Create free account